Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07040774

Natural History of Type 1 Interferonopathies: Insights From a European Cohort

Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.

Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.

In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.

The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.

The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical University Innsbruck, Innsbruck, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Genetically confirmed patient with type I interferonopathy
  • Patient affiliated to a social security scheme or beneficiary of such a scheme.

Exclusion criteria

  • Opposition of the patient and/or parental authority if the patient is a minor, to participation in the study.

Treatment and study plan

Primary outcomes

  1. Characterizing disease progression in pediatric and adult patients with type I interferonopathies

    Time frame: 2025-2045

    Composite description of phenotypes of patients with type I interferonopathies according to genotype (clinical, biological) over time.

Secondary outcomes

  1. Identifing and characterising genotype-specific immunological factors

    Time frame: 2025-2045

    Description of specific immunological factors according to genotype

  2. Research of biomarkers for diagnosis, prognosis and monitoring of disease activity

    Time frame: 2025-2045

    Biomarkers identified for diagnosis, prognosis and monitoring of disease activity

  3. Monitoring of treatment response according to phenotype and genotype

    Time frame: 2025-2045

    Treatment response by phenotype and genotype

Study contacts

Contact information is provided by the study sponsor or research team.

Marie-Louise FREMOND, Pr

CONTACT

[email protected]

01 44 49 48 24

Sponsors and collaborators

Lead sponsor

Imagine Institute

Other

Registry information

Acronym: EU-IFNp

Important dates

Study start
2025
Primary completion
2045
Study completion
2045
First posted
Jun 27, 2025
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.